Atrasentan · Vanrafia
Small molecule
Evidence outlook
Approved: IgA Nephropathy
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
The proteinuria result supported accelerated approval. The confirmatory eGFR comparison at week 136 was not statistically significant (2.39 mL/min/1.73m2 vs placebo, 2-sided p=0.057; Novartis, 13 February 2026).
track record: Partial signal
Also approved (1)
- Reduction of proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression (accelerated/conditional approval; Chinese brand Nuoruida)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ALIGN NCT04573478 · IgA Nephropathy, Immunoglobulin A Nephropathy ALIGN is a randomised, double-blind, placebo-controlled Phase 3 trial in IgA nephropathy (404 enrolled). Its registered primary endpoint, the change in proteinuria at week 36, was met (difference -36.1 percentage points, P<0.001) and supported accelerated approval. Proteinuria is a laboratory marker rather than a clinical outcome, and the confirmatory kidney-function comparison did not reach statistical significance (see the caveat), so the grade is moderate. The proteinuria result supported accelerated approval. The confirmatory eGFR comparison at week 136 was not statistically significant (2.39 mL/min/1.73m2 vs placebo, 2-sided p=0.057; Novartis, 13 February 2026). Registry: NCT04573478 | 3 | Double-blind period: Change in proteinuria (Up to Week 36 or approximately 9 months); Open-label period: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) (From open-label baseline up to end of treatment visit, up to 48 weeks); Open-label period: Number of Subjects With Adverse Events of Special Interest (AESI) Including Events of Fluid Overload (From open-label baseline up to end of treatment visit, up to 48 weeks); Substudy period: Number of subjects with TEAEs (From substudy baseline to end of treatment, up to 48 weeks); Substudy period: Number of subjects with AESI (From substudy baseline to end of treatment, up to 48 weeks) 2028-04-14 | Primary (interim, first 270 patients): 24-hour UPCR change at week 36, atrasentan -38.1% vs placebo -3.1%; between-group difference -36.1 percentage points (95% CI -44.6 to -26.4), P<0.001 | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Phase 4 (1)
What this study did
Competitive landscape
Other Endothelin A receptor drugs
Ambrisentan, Zibotentan + Dapagliflozin, F230. Compare all 4 Endothelin A receptor drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for IgA Nephropathy: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Atrasentan (Vanrafia): this drug | Approved | Small molecule | Endothelin A receptor | Partial signal | NCT04573478: Primary (interim, first 270 patients): 24-hour UPCR change at week 36, atrasentan -38.1% vs placebo -3.1%; between-group difference -36.1 percentage points (95% CI -44.6 to -26.4), P<0.001 | |
| Ambrisentan (Letairis) | Approved(overall) | Small molecule | Endothelin A receptor | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Atacicept | Approved | Protein / enzyme therapeutic | BLyS/APRIL (B-cell activating factor/a proliferation-inducing ligand) | Partial signal | Featured results are non-efficacy only in this race | |
| Budesonide (targeted-Release) (TARPEYO / Nefecon) | Approved | Small molecule | Glucocorticoid receptor | Reliable signal | No reviewed efficacy summary in this indication | |
| Iptacopan (Fabhalta) | Approved | Small molecule | Complement Factor B | Partial signal | NCT04578834: Final analysis: annualized total eGFR slope over 24 months, iptacopan -3.10 vs placebo -6.12 mL/min/1.73 m2 per year; difference 3.02 (95% CI 2.02 to 4.01), adjusted P<0.001. Interim (month 9): 24-hour UPCR 38.3% lower with iptacopan (95% CI 26.0 to 48.6), P<0.001. Both primaries met. | |
| Ravulizumab (Ultomiris) | Approved | Monoclonal antibody | Complement C5 | Partial signal | NCT06291376: Primary 1, change in 24-hour UPCR at week 34 (prespecified interim analysis), ravulizumab vs placebo: the sponsor reports a statistically significant and clinically meaningful reduction, met; figures not yet published. Primary 2, change in eGFR at week 106: not yet reported; the trial is ongoing. | |
| Sparsentan (Filspari) | Approved | Small molecule | Angiotensin II receptor type 1 (AT1R) + Endothelin receptor type A (ETA) | Partial signal | Featured results are non-efficacy only in this race | |
| Felzartamab | Phase 3 | Monoclonal antibody | CD38 | not yet graded | No reviewed efficacy summary in this indication | |
| JADE101 | Phase 3 | Monoclonal antibody | APRIL (A Proliferation-Inducing Ligand, TNFSF13) | not yet graded | No reviewed efficacy summary in this indication | |
| Mezagitamab | Phase 3 | Monoclonal antibody | CD38 | not yet graded | No reviewed efficacy summary in this indication | |
| Povetacicept | Phase 3 | Protein / enzyme therapeutic | BAFF / APRIL | not yet graded | No reviewed efficacy summary in this indication | |
| Sefaxersen | Phase 3 | RNA / oligonucleotide | Complement factor B (CFB) | Partial signal | NCT05797610: Prespecified interim analysis: statistically significant reduction in proteinuria (24-hour UPCR) vs placebo at week 37 (2026-09-23). | |
| Telitacicept | Phase 3 | Protein / enzyme therapeutic | BAFF / APRIL | not yet graded | No reviewed efficacy summary in this indication | |
| Zibotentan + Dapagliflozin | Phase 3(overall) | Small molecule | Endothelin A receptor, SGLT2 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Zigakibart | Phase 3 | Monoclonal antibody | APRIL (A Proliferation-Inducing Ligand, TNFSF13) | not yet graded | No reviewed efficacy summary in this indication | |
| Ebribafusp Alfa | Phase 2 | Protein / enzyme therapeutic | C3d / Factor H | not yet graded | No reviewed efficacy summary in this indication | |
| SCTC21C | Phase 1/2 | Biologic (subtype unspecified) | CD38 | not yet graded | No reviewed efficacy summary in this indication | |
| ARO-CFB | Phase 1 | RNA / oligonucleotide | Complement factor B (CFB) mRNA | not yet graded | No reviewed efficacy summary in this indication | |
| Opemalirsen | Phase 1(overall) | RNA / oligonucleotide | — | not yet graded | No reviewed efficacy summary in this indication | |
| F230 | —(overall) | Small molecule | Endothelin A receptor | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Vanrafia (Atrasentan) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent